GLPwatch

A Research Study Looking at How Oral Semaglutide Works in People With Type 2 Diabetes in Mexico, as Part of Local Clinical Practice

NCT05316662 · Completed

Last updated 2026-05-28

This study is testing how well an oral medication called semaglutide lowers blood sugar levels in adults with type 2 diabetes in Mexico as part of routine medical care.

Status Completed The study has finished.
Type Observational
Participants 187 people
Who can join Ages 18+ · all sexes
Timeline Started 2022-04 · est. completion 2024-04
Where 2 sites · Mexico

What this study is testing ClinicalTrials.gov NCT05316662 ↗

Description as written by the study sponsor.

The purpose of the study is to collect information on how Rybelsus® works in people with type 2 diabetes and to see if Rybelsus® can lower participant's blood sugar levels. Participants will get Rybelsus® as prescribed by the study doctor. The study will last for about 8-10 months. Participant will be asked to complete a questionnaire about how the participant will take Rybelsus® tablets. Participant will complete this questionnaire during the normally scheduled visit with the study doctor. Participant will be asked to complete some questionnaires about diabetes treatment. Participant will complete these questionnaires during normally scheduled visits with the study doctor.

Treatments tested

Main thing measuredChange in HbA1c
SponsorNovo Nordisk A/S
Conditions studiedDiabetes Mellitus, Type 2
GLP-1 drugs semaglutide

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT05316662 ↗